This agent, by modulating FXR signaling, improves liver inflammation and fibrosis in NASH adult patients [111] and reduces intestinal inflammation in colitis rodent models [112]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.